Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

UBI Pharma (6562)

TPEX
Currency in TWD
Disclaimer
13.90
-1.95(-12.30%)
Closed
6562 Scorecard
Unusual trading volume
Fair Value
Unlock Value
Day's Range
12.9516.30
52 wk Range
10.0044.20
Prev. Close
15.85
Open
16
Day's Range
12.95-16.3
52 wk Range
10-44.2
Volume
2,051,385
Average Vol. (3m)
664,526
1-Year Change
-62.4%
Shares Outstanding
118,190,205
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More
How do you feel today about 6562?
Vote to see community's results!
or

UBI Pharma Company Profile

UBI Pharma Inc is a Taiwan-based company mainly engaged in development and manufacturing of protein drugs and special dosage-form drugs. The Company is engaged in research and development, manufacturing and sales of protein drugs and special dosage-form drugs, contract manufacturing of pharmaceuticals, and provision of contract research services. The protein drug product line includes erythropoietin (UB-851) biosimilar drugs, innovative long-acting erythropoietin (UB-852), innovative long-acting granular ball community stimulating hormone (UB-853), and others used to treat anemia, neutropenia. The small molecule new drug product line includes B-Raf kinase inhibitor (UB-941) for the treatment of melanoma. The special scientific name drug product line includes tablets Olanzapine and Nevirapin for the treatment of schizophrenia and AIDS, and injections Granisetronl and Meropenen for the treatment of bacterial infections. It sells products in the domestic market and overseas markets.

Employees
0
Market
Taiwan
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.